Results 61 to 70 of about 6,581 (105)

[Research progress on the quercetin target role and signaling pathway in anti-liver fibrosis]. [PDF]

open access: yesZhonghua Gan Zang Bing Za Zhi
Zhao RQ   +9 more
europepmc   +1 more source

[Advances in targeted therapies for chronic spontaneous urticaria]. [PDF]

open access: yesZhejiang Da Xue Xue Bao Yi Xue Ban
Zhou L, Hu C, Wang S, Zhang R.
europepmc   +1 more source

[Effect of interleukin-33 on glucocorticoid-induced osteonecrosis of the femoral head in mice]. [PDF]

open access: yesZhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
Li H   +7 more
europepmc   +1 more source

[How I treat vasovagal syncope in children]. [PDF]

open access: yesZhongguo Dang Dai Er Ke Za Zhi
Zou RM, Wang C.
europepmc   +1 more source

血管紧张素Ⅱ受体阻断剂在老年2型糖尿病患者中的应用

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 2008
【目的】 评估血管紧张素Ⅱ受体阻断剂(ARB)在老年糖尿病患者中应用的有效性和安全性?【方法】 56例大于65岁老年2型糖尿病患者,随机分为治疗组和对照组,治疗组予氯沙坦口服,剂量50 ~ 100 mg/d,对照组不给上述治疗?饮食?运动?降糖?降脂等治疗方法两组相同?观察患者预先设定的研究终点事件的发生率(研究终点包括血清肌酐浓度的加倍,发生终末期肾脏疾病以及死亡)和不良事件发生情况?【结果】 经过1年的观察,氯沙坦治疗组能有效地降低试验的主要研究终点发生的危险性?不良事件(如血肌肝的升高和高钾血症 ...
doaj  

[Perioperative management of a patient with Kennedy disease undergoing knee replacement: A case report]. [PDF]

open access: yesBeijing Da Xue Xue Bao Yi Xue Ban
Bai P, Zhang H, Wang J, Zhu H, Zeng H.
europepmc   +1 more source

Home - About - Disclaimer - Privacy